Orthofix International N.V. (NASDAQ:OFIX) issued an update on its FY17 earnings guidance on Monday morning. The company provided EPS guidance of $1.54-1.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.53. The company issued revenue guidance of $422-425 million, compared to the consensus revenue estimate of $414.14 million.

Orthofix International N.V. (NASDAQ:OFIX) traded up 1.98% during mid-day trading on Monday, reaching $44.85. The company’s stock had a trading volume of 110,598 shares. The stock’s market cap is $809.27 million. Orthofix International N.V. has a one year low of $32.51 and a one year high of $47.18. The firm’s 50 day moving average is $45.55 and its 200-day moving average is $40.42.

Orthofix International N.V. (NASDAQ:OFIX) last issued its earnings results on Thursday, May 4th. The medical device company reported $0.27 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.27. The business had revenue of $102.70 million for the quarter, compared to the consensus estimate of $97.17 million. Orthofix International N.V. had a negative net margin of 0.82% and a positive return on equity of 10.03%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.28 EPS. Equities analysts expect that Orthofix International N.V. will post $1.53 earnings per share for the current fiscal year.

OFIX has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of Orthofix International N.V. from a hold rating to a sell rating in a research note on Tuesday, May 9th. Ladenburg Thalmann Financial Services initiated coverage on shares of Orthofix International N.V. in a research note on Wednesday, June 14th. They issued a buy rating and a $53.25 target price on the stock. SunTrust Banks, Inc. initiated coverage on shares of Orthofix International N.V. in a research note on Tuesday, May 23rd. They issued a buy rating and a $49.00 target price on the stock. BidaskClub downgraded shares of Orthofix International N.V. from a strong-buy rating to a buy rating in a research note on Tuesday, July 25th. Finally, BTIG Research initiated coverage on shares of Orthofix International N.V. in a research note on Wednesday, June 21st. They issued a buy rating and a $52.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Orthofix International N.V. currently has a consensus rating of Buy and a consensus price target of $51.88.

ILLEGAL ACTIVITY NOTICE: “Orthofix International N.V. (OFIX) Issues FY17 Earnings Guidance” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/orthofix-international-n-v-ofix-issues-fy17-earnings-guidance.html.

About Orthofix International N.V.

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Earnings History and Estimates for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.